186 related articles for article (PubMed ID: 25414443)
21. T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone.
Sensi M; Salvi S; Castelli C; Maccalli C; Mazzocchi A; Mortarini R; Nicolini G; Herlyn M; Parmiani G; Anichini A
J Exp Med; 1993 Oct; 178(4):1231-46. PubMed ID: 8376931
[TBL] [Abstract][Full Text] [Related]
22. Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches.
Volpe G; Cignetti A; Panuzzo C; Kuka M; Vitaggio K; Brancaccio M; Perrone G; Rinaldi M; Prato G; Fava M; Geuna M; Pautasso M; Casnici C; Signori E; Tonon G; Tarone G; Marelli O; Fazio VM; Saglio G
Cancer Res; 2007 Jun; 67(11):5300-7. PubMed ID: 17545610
[TBL] [Abstract][Full Text] [Related]
23. CD79b expression in B cell chronic lymphocytic leukemia: its implication for minimal residual disease detection.
Garcia Vela J; Delgado I; Benito L; Monteserin M; Garcia Alonso L; Somolinos N; Andreu M; Oña F
Leukemia; 1999 Oct; 13(10):1501-5. PubMed ID: 10516749
[TBL] [Abstract][Full Text] [Related]
24. Targeting B cell leukemia with highly specific allogeneic T cells with a public recognition motif.
Abrahamsen IW; Stronen E; Wälchli S; Johansen JN; Kjellevoll S; Kumari S; Komada M; Gaudernack G; Tjonnfjord G; Toebes M; Schumacher TN; Lund-Johansen F; Olweus J
Leukemia; 2010 Nov; 24(11):1901-9. PubMed ID: 20844564
[TBL] [Abstract][Full Text] [Related]
25. Distribution of HLA-G alternative mRNAs including soluble forms in normal lymphocytes and in lymphoid cell-derived leukemia.
Amiot L; Onno M; Drénou B; le Marchand B; Lamy T; Semana G; Fauchet R
Eur J Immunogenet; 1996 Aug; 23(4):311-20. PubMed ID: 8858287
[TBL] [Abstract][Full Text] [Related]
26. [Treatment of lymphoblastic leukemia with CD19-specific modified chimeric antigen receptor T cells].
Li HH; Zhu P; Wu XQ; Liu YF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Dec; 22(6):1753-6. PubMed ID: 25543510
[TBL] [Abstract][Full Text] [Related]
27. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
Duong MN; Erdes E; Hebeisen M; Rufer N
J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
[TBL] [Abstract][Full Text] [Related]
28. Construction and molecular characterization of a T-cell receptor-like antibody and CAR-T cells specific for minor histocompatibility antigen HA-1H.
Inaguma Y; Akahori Y; Murayama Y; Shiraishi K; Tsuzuki-Iba S; Endoh A; Tsujikawa J; Demachi-Okamura A; Hiramatsu K; Saji H; Yamamoto Y; Yamamoto N; Nishimura Y; Takahashi T; Kuzushima K; Emi N; Akatsuka Y
Gene Ther; 2014 Jun; 21(6):575-84. PubMed ID: 24694533
[TBL] [Abstract][Full Text] [Related]
29. Isolation of human MHC class II-restricted T cell receptors from the autologous T-cell repertoire with potent anti-leukaemic reactivity.
Weigand LU; Liang X; Schmied S; Mall S; Klar R; Stötzer OJ; Salat C; Götze K; Mautner J; Peschel C; Krackhardt AM
Immunology; 2012 Nov; 137(3):226-38. PubMed ID: 23025755
[TBL] [Abstract][Full Text] [Related]
30. Low-cost generation of Good Manufacturing Practice-grade CD19-specific chimeric antigen receptor-expressing T cells using piggyBac gene transfer and patient-derived materials.
Ramanayake S; Bilmon I; Bishop D; Dubosq MC; Blyth E; Clancy L; Gottlieb D; Micklethwaite K
Cytotherapy; 2015 Sep; 17(9):1251-67. PubMed ID: 26212611
[TBL] [Abstract][Full Text] [Related]
31. Targeting B-cell neoplasia with T-cell receptors recognizing a CD20-derived peptide on patient-specific HLA.
Mensali N; Ying F; Sheng VO; Yang W; Walseng E; Kumari S; Fallang LE; Kolstad A; Uckert W; Malmberg KJ; Wälchli S; Olweus J
Oncoimmunology; 2016 May; 5(5):e1138199. PubMed ID: 27467957
[TBL] [Abstract][Full Text] [Related]
32. Are chimeric antigen receptor T cells ready for prime time?
Brentjens RJ
Clin Adv Hematol Oncol; 2016 Jan; 14(1):17-9. PubMed ID: 27057662
[No Abstract] [Full Text] [Related]
33. Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy.
Hill JA; Li D; Hay KA; Green ML; Cherian S; Chen X; Riddell SR; Maloney DG; Boeckh M; Turtle CJ
Blood; 2018 Jan; 131(1):121-130. PubMed ID: 29038338
[TBL] [Abstract][Full Text] [Related]
34. Unbiased Identification of T-Cell Receptors Targeting Immunodominant Peptide-MHC Complexes for T-Cell Receptor Immunotherapy.
Lorenz FKM; Ellinger C; Kieback E; Wilde S; Lietz M; Schendel DJ; Uckert W
Hum Gene Ther; 2017 Dec; 28(12):1158-1168. PubMed ID: 28950731
[TBL] [Abstract][Full Text] [Related]
35. TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies.
Ahmed M; Lopez-Albaitero A; Pankov D; Santich BH; Liu H; Yan S; Xiang J; Wang P; Hasan AN; Selvakumar A; O'Reilly RJ; Liu C; Cheung NV
JCI Insight; 2018 Feb; 3(4):. PubMed ID: 29467338
[TBL] [Abstract][Full Text] [Related]
36. B cell receptor accessory molecule CD79 gets involved in response against Streptococcus agalactiae infection and BCR signaling in Nile tilapia (Oreochromis niloticus).
Wu L; Bian X; Kong L; Yin X; Mu L; Wu S; Gao A; Wei X; Guo Z; Ye J
Fish Shellfish Immunol; 2019 Apr; 87():212-219. PubMed ID: 30648625
[TBL] [Abstract][Full Text] [Related]
37. CD19-Targeted chimeric antigen receptor-modified T-cell immunotherapy for B-cell malignancies.
Turtle CJ; Riddell SR; Maloney DG
Clin Pharmacol Ther; 2016 Sep; 100(3):252-8. PubMed ID: 27170467
[TBL] [Abstract][Full Text] [Related]
38. Mechanism of CD79A and CD79B Support for IgM+ B Cell Fitness through B Cell Receptor Surface Expression.
Huse K; Bai B; Hilden VI; Bollum LK; Våtsveen TK; Munthe LA; Smeland EB; Irish JM; Wälchli S; Myklebust JH
J Immunol; 2022 Nov; 209(10):2042-2053. PubMed ID: 36426942
[TBL] [Abstract][Full Text] [Related]
39. The shared tumor associated antigen cyclin-A2 is recognized by high-avidity T-cells.
Kondo E; Maecker B; Draube A; Klein-Gonzalez N; Shimabukuro-Vornhagen A; Schultze JL; von Bergwelt-Baildon MS
Int J Cancer; 2009 Nov; 125(10):2474-8. PubMed ID: 19681121
[TBL] [Abstract][Full Text] [Related]
40. Targeting CD79b for Chimeric Antigen Receptor T-Cell Therapy of B-Cell Lymphomas.
Ding S; Mao X; Cao Y; Wang N; Xu H; Zhou J
Target Oncol; 2020 Jun; 15(3):365-375. PubMed ID: 32495161
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
